BUY NOVOSARM – TESTOLONE (RAD140) (20 MG/ML – 30 ML)
MAIN PRODUCT DESCRIPTION
NovoSARM – Testolone (RAD140) 20 mg/ml contains Testolone, commonly known as RAD140, an investigational selective androgen receptor modulator (SARM). According to the supplied product information, RAD140 is a relatively recent compound in SARM research and was developed for investigation into potential therapeutic applications.
The supplied source describes RAD140 as a compound with strong affinity for the androgen receptor, a nuclear receptor through which testosterone and other androgens produce biological effects. SARMs are investigated because they are designed to modulate androgen receptors with a degree of tissue selectivity that differs from conventional anabolic-androgenic steroids.
PRODUCT SPECIFICATIONS
- Product: NovoSARM – Testolone
- Alternative name: RAD140
- Strength: 20 mg/ml
- Pack Size: 30 ml
- Active Compound: Testolone (RAD140)
- Pharmacological Class: Selective Androgen Receptor Modulator
- Dosage Form: Liquid preparation
- Route: Not specified in the supplied information
- Regulatory Status: Investigational
- Developer stated in source: Radius Health
The supplied information does not provide a molecular formula, molecular weight, CAS number, manufacturer specification or verified marketing authorisation for this presentation. These details have therefore not been added.
PHARMACOLOGICAL BACKGROUND
RAD140 is designed to interact with androgen receptors. Androgen receptors are found in multiple tissues and regulate the expression of genes involved in androgen-dependent biological processes.
Testosterone and other androgenic hormones activate these receptors naturally. A synthetic androgen receptor modulator such as RAD140 is designed to alter receptor signalling through selective binding characteristics.
The supplied information describes RAD140 as having a strong affinity for the androgen receptor and discusses activity involving muscle tissue and prostate-related pathways. However, the degree of tissue selectivity can depend on the experimental model and the dose, and it should not be interpreted as meaning that RAD140 affects only skeletal muscle.
DEVELOPMENT AND RESEARCH HISTORY
The supplied source states that RAD140 is an investigative compound developed by Radius Health and that early animal studies were conducted in 2011.
The source describes Testolone as a promising research compound because of its proposed ability to stimulate anabolic signalling while producing a different tissue activity profile from traditional anabolic steroids.
These observations represent the context of investigational research. They do not establish RAD140 as a clinically approved treatment.
ANDROGEN-RECEPTOR ACTIVITY
The principal pharmacological interest in RAD140 is its interaction with the androgen receptor.
In skeletal muscle, androgen-receptor activation can influence gene transcription associated with protein metabolism and muscle tissue maintenance. This is one reason SARMs have been investigated for disorders involving muscle loss.
The supplied source associates Testolone with increased muscle mass and describes activity in muscle tissue. These statements should remain within the research context and should not be presented as guaranteed outcomes for individuals using the product.
MUSCLE-WASTING RESEARCH
The supplied product material discusses potential applications in cachexia and age-related muscle wasting.
Muscle wasting associated with cancer, chronic illness or ageing is an important area of medical research because loss of lean tissue can affect physical function and quality of life. Selective androgen receptor modulation has been studied as a possible pharmacological approach to this problem.
However, the supplied information does not provide sufficient clinical evidence or regulatory documentation to establish RAD140 as an approved treatment for cachexia, sarcopenia or age-related muscle loss.
PROSTATE-RELATED CLAIMS
The source states that RAD140 may stimulate muscle tissue while having only partial activity in prostate tissue. It also claims that the compound does not affect the prostate in men.
These statements should be treated cautiously. Androgen receptors occur in multiple tissues, and tissue selectivity is a relative pharmacological property rather than a guarantee that a compound has no effect on other androgen-responsive organs.
No independent clinical evidence or regulatory documentation has been supplied to establish that RAD140 has no prostate-related effects.
FEMALE ANDROGENIC EFFECTS
The supplied information states that RAD140 does not cause androgenic symptoms in women.
This claim has not been presented as a safety guarantee. The supplied product information does not provide a comprehensive clinical safety profile in women or sufficient evidence to establish that androgen-related effects cannot occur.
LIVER-RELATED CLAIMS
The supplied source states that Testolone can increase muscle mass without elevation of liver enzymes.
This should not be interpreted as proof that RAD140 is non-hepatotoxic or incapable of affecting liver function. A lack of reported liver-enzyme elevation in a particular study or experimental setting does not establish a universal absence of hepatic risk.
The supplied information does not provide a complete long-term safety assessment for liver function.
FITNESS AND BODYBUILDING CONTEXT
RAD140 has attracted attention in fitness communities because of its proposed anabolic activity. The supplied source presents it as a compound capable of producing effects similar to those associated with anabolic steroids.
Those claims should be distinguished from established clinical indications. RAD140 should not be marketed as an approved bodybuilding medicine, muscle-building treatment or athletic-performance enhancer.
No validated human dosing protocol for bodybuilding or performance use has been supplied.
SAFETY AND ENDOCRINE CONSIDERATIONS
Although RAD140 is designed to be selective, it acts on a major endocrine signalling system. Modulating androgen receptors can potentially affect hormonal regulation beyond the intended target tissue.
The supplied information does not provide a complete list of adverse reactions, contraindications, drug interactions or long-term safety outcomes. The absence of such information should not be interpreted as evidence that RAD140 is risk-free.
Because it is an investigational compound, appropriate scientific evaluation and professional oversight are particularly important.
REGULATORY STATUS
The supplied source describes Testolone (RAD140) as an investigational drug being developed and researched for potential therapeutic applications.
No EU marketing authorisation, national medicinal-product authorisation number, approved therapeutic indication or official prescription status was provided for the specific 20 mg/ml, 30 ml preparation.
Accordingly, NovoSARM – Testolone should not be described as an EU-authorised medicine or as an approved treatment for muscle wasting, cachexia, ageing or athletic performance.
IMPORTANT RESEARCH NOTICE
Testolone (RAD140) is an investigational SARM. The supplied product material describes research into androgen-receptor activity, muscle tissue and potential therapeutic applications, but these findings do not establish clinical efficacy or long-term safety.
Statements concerning muscle growth, prostate selectivity, liver enzymes or reduced androgenic effects should therefore not be presented as guaranteed outcomes.
This product information is based solely on the supplied source material and is intended for general research and product information. It does not constitute medical advice, an approved treatment recommendation or instructions for non-prescribed human use.
